Droperidol on Prevention of Cannabis Hyperemesis Syndrome

• Status: Recruiting
• Trial end date: 2023-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mercy Health Ohio
• Collaborator: Lake Erie College of Osteopathic Medicine
• Treatments: Diphenhydramine; Droperidol; Promethazine

Criteria

Inclusion Criteria:

• aged 18 years of age or older and presenting with cannabis hyperemesis syndrome requiring intravenous medication.

Exclusion Criteria:

• any patient with a contraindication to the use of droperidol

• QTc interval on ECG greater than 440 milliseconds for males and greater than 450 milliseconds for females

• any prisoners

• pregnant females.